Showing posts with label COPD. Show all posts
Showing posts with label COPD. Show all posts

Monday, June 2, 2008

Researchers Identify Determinants of COPD Exacerbation Frequency: Presented at ATS

TORONTO -- May 26, 2008 -- Chronic intermittent pulsed therapy with moxifloxacin provided significant reductions in the frequency of exacerbations in chronic obstructive pulmonary disease (COPD), according to findings presented here at the 104th International Conference of the American Thoracic Society (ATS).

The results were presented here on May 18 by lead author Sanjay Sethi, MD; Attending Physician; Department of Pulmonary, Critical Care, and Sleep Services; Veterans Affairs Western New York Healthcare System in Buffalo, New York.

Frequent exacerbations of COPD increase both morbidity and mortality. They may result in a faster decline of lung function and may lead to a significant reduction in quality of life. Reducing both the frequency and severity of these exacerbations is one of the main goals of maintenance therapy.

Long-acting bronchodilators and inhaled corticosteroids are commonly used but have only moderate efficacy.

In a poster presentation, Dr. Sethi said that as many as 40% to 50% of COPD exacerbations may be related to bacterial infections. Bacterial strains that are new to patients are thought to be the main cause of acute exacerbations. Current therapeutic approaches focus on treating the exacerbations as they happen.

An effective suppressive regimen might involve disrupting the cycle of chronic bacterial colonisation and chronic inflammation, which might lead to fewer exacerbations.

That rationale led to this randomised, double-blind, parallel-group, multicentre trial conducted at 76 centres in 15 countries. Treatment was administered for 5 days every 8 weeks for a total of 6 courses. Patients were randomised to moxifloxacin 400 mg once daily or placebo once daily.

Patients were evaluated for exacerbations and adverse events for up to 24 weeks post-treatment.

The primary efficacy endpoint was frequency of exacerbations from randomisation to the end of treatment at 48 weeks in the per-protocol (PP) end-of-therapy (EOT) population.

A total of 1,404 patients were assessed for eligibility; 573 patients were randomised to receive moxifloxacin and 584 to placebo. Four patients in each group did not receive treatment, thus the intention-to-treat (ITT) arms had 569 and 580 patients, respectively. The PP EOT populations consisted of 351 patients in the moxifloxacin group and 387 in the placebo arm.

Approximately 31% of PP EOT patients in both arms were colonised by a respiratory pathogen at baseline. Approximately 10% of both groups were colonised by Haemophilus influenzae at baseline.

In both the ITT and the PP EOT groups, the significant variables influencing the number of exacerbations (P <= .05) were the severity of the underlying COPD as measured by the percent of predicted forced expiratory volume, treatment versus placebo, number of exacerbations in the previous year (<2>=2), and baseline colonisation with H influenzae (no baseline colonisation vs colonisation).

Geographic regions also demonstrated significant differences. Each region was compared with the mean value for all the other regions. In the ITT population, the use of systemic corticosteroids was an additional risk factor for exacerbations.

The study results also confirmed that antibiotics such as the fluoroquinolone moxifloxacin may provide benefits to maintenance therapy by preventing exacerbations and the subsequent inflammatory response, the researchers noted.


Original article located at www.docguide.com


Disability Lawyer Blog: Links & Free Case Evaluation


Click to Ask a Question from a:
Social Security Disability Attorney

Free Disability Case Evaluation from a:

Social Security Disability Lawyer


Resources: Looking for Additional Social Security Disability information?

  • Need to apply for Social Security Disability?
  • Have you been denied Social Security Disability?
  • Do you want to appeal a Social Security Disability case?

www.NationalDisabilityLawyer.com

1-800-507-4774


NationalDisabilityLawyer.com is a website with SSDI and SSI Disability information. Learn more about disability cases, how to apply for disability and how to appeal a denied Social Security Disability case.

Sunday, June 1, 2008

Review suggests asthma drugs safe, effective in COPD

NEW YORK (Reuters Health) - Previous research has linked a class of asthma drugs known as long-acting beta agonists to increased risk of adverse respiratory-related events or death in patients with COPD (chronic obstructive pulmonary disease).

However, a report published this month indicates this may not be the case.

The new report suggests that long-acting beta agonists have beneficial effects in patients with moderate-to-severe COPD and do not appear to increase the risk of respiratory deaths. Examples of long-acting beta agonists used to treat asthma and other respiratory conditions include Advair, Serevent, Foradil and Symbicort.

In the study, Dr. Gustavo J. Rodrigo, from Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay and colleagues pooled data from 27 randomized clinical trials that compared two long-acting beta agonists with placebo or with two long-acting "anticholinergic" asthma drugs (for example, Spiriva) in patients with moderate to severe COPD.

Compared with placebo, long-acting beta agonist therapy reduced severe COPD flare-ups by 21 percent and did not increase death from COPD.

Treatment with a long-acting beta agonist had benefits "in terms of lung function, quality of life, and use of daily rescue medication" with short-acting beta agonists, Rodrigo noted in comments to Reuters Health.

However, in an editorial published with the study in the journal Chest, Dr. Malcolm R. Sears from McMaster University, Hamilton, Ontario, Canada, urges caution in applying this finding to the real world. "In COPD trials, patients are carefully selected and monitored, and asthma is generally excluded. In real life, asthma and COPD can be hard to disentangle especially in older patients," he writes.

Hence, accepting the current results that a long-acting beta agonist alone is appropriate and safe in patients with COPD "may put some patients who in fact have asthma at risk if treated in this manner," Sears warns.

Rodrigo's team also found that treatment with a long-acting beta agonist combined with an inhaled steroid was associated with lower respiratory death compared with a long-acting beta agonist alone.

"Given the reduced mortality with the use of inhaled corticosteroids in combination with long-acting beta-2 agonist therapy, one would argue that, in COPD, concomitant inhaled corticosteroid therapy is preferable to long-acting beta-2 agonist monotherapy," Rodrigo told Reuters Health.

The pooled data also showed that treatment with Spiriva decreased the incidence of severe COPD flare-ups compared with a long-acting beta agonist.

Commenting on this finding, Sears writes: "Overall, daily tiotropium (Spiriva) appears to be foundational as a long-acting bronchodilator in COPD, despite some equivocation on this matter in current COPD treatment guidelines."





Original article located at http://uk.reuters.com/article/healthNews/idUKCOL65323520080526


Disability Lawyer Blog: Links & Free Case Evaluation


Click to Ask a Question from a:
Social Security Disability Attorney

Free Disability Case Evaluation from a:

Social Security Disability Lawyer


Resources: Looking for Additional Social Security Disability information?

  • Need to apply for Social Security Disability?
  • Have you been denied Social Security Disability?
  • Do you want to appeal a Social Security Disability case?

www.NationalDisabilityLawyer.com

1-800-507-4774


NationalDisabilityLawyer.com is a website with SSDI and SSI Disability information. Learn more about disability cases, how to apply for disability and how to appeal a denied Social Security Disability case.

Tuesday, May 6, 2008

COPD disability for SSI and SSDI

COPD (Cardiac Obstructive Pulmonary Disease) is a condition that is difficult for suffers. Before you consider seeking legal advice for a SSI Disability or SSDI case, ensure you are seeing your doctor on a regular basis as recommended. It is important to talk to your Cardiac Obstructive Pulmonary Disease condition.

COPD Symptoms and Social Security Disability:
Make sure you are describing your chest pain to your COPD doctor. Also, make sure you are talking about how long your must rest to recover. This information is critical to document to win a COPD disability case.

COPD Social Security Lawyer:
Click on the COPD Social Security Lawyer link to learn more information about Cardiac Obstructive Pulmonary Disease and how a Social Security lawyer can help. Also, in the below text is a free case evaluation form you can submit and a 1-800 number for you to call.


Disability Lawyer Blog: Links & Free Case Evaluation


Click to Ask a Question from a:
Social Security Disability Attorney

Free Disability Case Evaluation from a:

Social Security Disability Lawyer


Resources: Looking for Additional Social Security Disability information?

  • Need to apply for Social Security Disability?
  • Have you been denied Social Security Disability?
  • Do you want to appeal a Social Security Disability case?

www.NationalDisabilityLawyer.com

1-800-507-4774


NationalDisabilityLawyer.com is a website with SSDI and SSI Disability information. Learn more about disability cases, how to apply for disability and how to appeal a denied Social Security Disability case.

Friday, March 28, 2008

COPD Disability Impairment SSDI and SSI Benefits

COPD or Cardiac Obstructive Pulmonary Disease is a condition that is difficult to control and qualifies for Social Security Disability (SSDI, and SSI Disability) benefits. To win disability benefits for a COPD case, the claimant must provide documentation that fulfills the SSA requirements (Social Security Administration) for disability benefits.

COPD patients should see their doctor regularly. Make sure you inform your doctor if you are feeling shortness of breath--tell your doctor how often this occurs and when it happens. For example, do you feel shortness of breath when you are walking across a room, carrying a bag or groceries, etc). Have you been experiencing chest pain? If you are, make sure to describe this chest pain to your doctor. Tell your doctor how long you must rest to recover from chest pain. This information helps your doctor adjust your COPD treatment plan and later will help you with your Social Security disability claim because this information should also be recorded by your doctor in your medical records.

For matters of a COPD SSDI or COPD SSI Disability claim, it is important to gather medical documentation to help present your COPD disability benefits claim to the Social Security Administration. If you are not currently working with a disability attorney with Cardiac Obstructive Pulmonary Disease disability benefits experience, you may want to consider contacting a COPD Social Security Disability Attorney. Your disability benefits attorney will help you present the proper questions to your doctors and can be a resource through the disability claims process.


COPD: More information and SSDI and SSI resources

For more information about COPD, please review COPD International. For more information about Cardiac Obstructive Pulmonary Disease disability impairments and how it can impact a SSDI or SSI Disability benefits claim, please consider contacting a COPD Social Security Disability Lawyer.

COPD Attorney Fees and COPD Disorder Lawyer Fees

Many disability lawyers and disability attorneys will only charge a fee if they are able to win disability benefits (SSDI and SSI Disability). This means you have nothing to lose and everything to gain by reaching out to an attorney that is experienced with COPD disability cases. Click on the links to see more information about a COPD disability lawyer fee and a COPD disability attorney fee structure for COPD Social Security disability cases.



Click for a free case evaluation from a Social Security disability lawyer.